This in-person training is designed for clinicians at OCHF Behavioral Health providing Level 1.0 Outpatient and Level 0.5 Early Intervention services for adolescent and adult populations. The session will focus on applying the ASAM 4th Edition with an emphasis on treatment services for individuals diagnosed with Opioid Use Disorder (OUD). The training will provide foundational education on Suboxone and Vivitrol, two commonly used forms of Medication-Assisted Treatment (MAT), including how these medications intersect with counseling services. Additional focus areas include strategies for continuing care following discharge and recent updates to 42 CFR Part 2.
Learning Objectives:
By the end of this training, participants will be able to:
- Describe the key changes and clinical applications of the ASAM 4th Edition for Level 1.0 and 0.5 services.
- Explain the role of suboxone and Vivitrol in treating Opioid Use Disorder and how to support clients receiving MAT within a counseling framework.
- Identify appropriate continuing care strategies to support individuals post-discharge in rural settings
- Summarize recent updates to 42 CFR Part 2 and how these changes affect confidentiality and care coordination in outpatient settings.
Presented by: Mark Disselkoen, MSSW, LCSW, LCADC
Mark Disselkoen, is Senior Project Manager at the Center for the Application of Substance Abuse Technologies (CASAT) at the University of Nevada, Reno since 2003. He is an LCSW and LCADC and has worked in the field of substance use and mental health treatment for over 30 years. He oversees the CCBHC project and certification and training/technical assistance contracts in Nevada and provides numerous trainings in the field of substance use and mental health treatment.
Continuing Education Units: 6 CEUs
This training is approved for continuing education by the boards listed here.
Funding for this activity was made possible in whole or in part by the Nevada Department of Health and Human Services (DHHS) Director’s Office through the Fund for a Resilient Nevada, established in Nevada Revised Statutes 433.712 through 433.744. The opinions, findings, conclusions, and recommendations expressed in our courses are those of the author(s) and do not necessarily represent the official views of the Nevada Opioid Center of Excellence or its funders.